"The Biotechnology Edge”
Insights from Lab Bench to Patient Bedside
The Clinical Path of an AD Therapeutic
April 24th, 2019
5:00 - 6:00pm
Cannon Room, HMS
Food will be provided!
Speaker: Vissia Viglietta, MD, PhD
Dr Viglietta is a Global Development Leader and Global Product General Manager at Amgen. She is leading the late stage development of the BACE inhibitor CNP520 for the prevention of Alzheimer’s disease and the TREM2 program for AD. Her major research interest has been in elucidating the role of autoreactive T cells and regulatory cells in autoimmune diseases such as multiple sclerosis.